How Does Chronic Kidney Disease Lead To Anemia?

Chronic kidney disease (CKD) leads to anemia mainly because damaged kidneys produce less erythropoietin (EPO)—the hormone that signals bone marrow to make red blood cells—and because inflammation in CKD raises hepcidin, which traps iron in stores and blocks its use, causing iron-restricted erythropoiesis. Additional contributors include shortened red cell lifespan, uremic toxins that blunt marrow response, nutritional deficits, and blood loss (especially with dialysis). According to KDIGO’s 2025 Anemia in CKD guideline (public review draft, Nov 2024), EPO deficiency and hepcidin-driven iron restriction are central mechanisms in CKD anemia.

How Does Chronic Renal Failure Lead To Anemia?

In advanced CKD (chronic renal failure), peritubular interstitial cells in the kidney produce less EPO, which leads to reduced red blood cell (RBC) production and apoptosis of erythroid precursors in bone marrow. StatPearls (Vaidya et al., updated July 22, 2024) emphasizes EPO deficiency as the hallmark of CKD anemia and notes that pro-inflammatory cytokines further suppress erythropoiesis.

Iron handling is also disrupted: chronic inflammation elevates hepcidin, reducing intestinal iron absorption and preventing iron release from macrophages and the liver, leading to functional iron deficiency despite normal or high ferritin. KDIGO 2025 highlights hepcidin’s role in iron-restricted erythropoiesis in CKD due to persistent inflammation and declining renal clearance.

Beyond EPO and iron, other factors worsen anemia: uremic toxins blunt marrow responsiveness, RBC lifespan shortens, and comorbid deficiencies of B12/folate or dialysis-related blood loss can contribute. A 2021 review in Frontiers in Medicine (Santos-Araújo et al., Mar 25, 2021) synthesizes these mechanisms and the interplay of HIF, erythroferrone, and iron transport genes in stress erythropoiesis.

How Common Is Anemia In CKD Patients In India?

Anemia is frequent and increases with CKD stage, though exact prevalence varies by setting and methodology. A 2023 open-access synthesis reports prevalence around 39.36% among CKD in India, with higher rates at advanced stages, contrasting 14% in the USA and over 50% in several low- and middle-income regions; stage-wise global estimates cited were 22.4%, 41.3%, and 53.9% for CKD stages 3, 4, and 5, respectively (Bishaw et al., 2023).

Regional Indian data remain heterogeneous, but local cross-sectional studies often show high burdens, especially in late stages and resource-limited contexts. For instance, a 2025 cross-sectional analysis from Odisha CKD hotspot villages reported anemia in 85.7% of CKD and 89.2% of CKDu patients, with microcytic patterns common—underscoring the roles of iron deficiency, environment, and late presentation (Das et al., Journal of Clinical Nephrology, Apr 15, 2025).

Smaller Indian reports similarly cite wide ranges (30–90%) driven by nutrition, access to care, and diagnostic criteria; a pragmatic Indian overview described rising prevalence from about 20% at Stage 1 to over 90% at Stage 5, highlighting the stage dependence and systemic contributors in LMIC settings.

What Are The Symptoms Of Anemia In Chronic Kidney Disease Patients?

Typical symptoms include fatigue, reduced exercise tolerance, shortness of breath, palpitations, headaches, lightheadedness, and pallor; in CKD, anemia can also exacerbate angina, heart failure symptoms, cognitive changes, and restless legs. Educational and clinical reviews (e.g., StatPearls 2024 and Medscape overview) link CKD anemia to quality-of-life decline and increased cardiovascular risk, reinforcing the need for routine hemoglobin checks aligned with CKD stage.

Because CKD patients may also have fluid overload and metabolic acidosis, anemia-related dyspnea or weakness can be mistaken for other complications; structured assessment with hemoglobin, ferritin, transferrin saturation (TSAT), and markers of inflammation helps clarify causation. KDIGO 2025 recommends tailored lab evaluation to identify absolute versus functional iron deficiency and to guide therapy.

How To Treat Anemia In People With CKD?

Here are some ways to treat anemia in people with CKD but do not try any of the below without any medical supervision.

• Correct iron deficiency first: KDIGO 2025 advises iron repletion for low TSAT and/or ferritin thresholds, with intravenous iron favored in many CKD settings for efficacy and to overcome hepcidin-mediated absorption limits. A prospective analysis from the FIND-CKD program showed hepcidin rises with both IV and oral iron and correlates with ferritin, reflecting store repletion, though hepcidin is variable and not a sole guide for response (Macdougall et al., PLoS One, 2016).
• Use erythropoiesis-stimulating agents (ESAs) when indicated: After iron optimization, ESAs can raise hemoglobin by replacing deficient EPO; targets should avoid normalization to minimize cardiovascular risks noted in prior trials. StatPearls (2024) summarizes ESA use per KDIGO, emphasizing individualized targets and safety monitoring.
• Consider HIF–prolyl hydroxylase inhibitors (HIF-PHIs): These oral agents stabilize HIF, increasing endogenous EPO and improving iron utilization; guideline discussions anticipate selective use where approved, with ongoing safety surveillance reflected in KDIGO 2025 deliberations.
• Address contributors: Treat inflammation and infection, manage dialysis adequacy and blood loss, correct B12/folate deficits, and avoid nephrotoxic or marrow-suppressive drugs where possible. Reviews in Frontiers in Medicine and kidney-focused iron management texts highlight the need for holistic correction of iron metabolism and marrow responsiveness.
• Monitor and adjust: KDIGO 2025 proposes risk- and response-based monitoring of hemoglobin, ferritin, and TSAT, increasing frequency at higher CKD stages or when starting/changing therapy; shared decision-making should weigh transfusion avoidance against cardiovascular risks in ESA therapy.

According to research synthesized by Awdishu and colleagues in AJHP (June 10, 2025), KDIGO 2024/2025 updates integrate renoprotective therapies with anemia management, emphasizing iron-first strategies, judicious ESA use, and comprehensive cardiovascular risk control.

Practical perspective for Siliguri, West Bengal

Given high background rates of iron deficiency and late CKD presentation in many Indian settings, intravenous iron can be particularly effective, especially when inflammation and hepcidin limit oral absorption. Local data from eastern India suggest substantial anemia prevalence in advanced CKD and CKDu communities, underscoring the need for early screening with hemoglobin, ferritin, and TSAT in high-risk populations.

Coordination of anemia care alongside blood pressure, diabetes control, and SGLT2/RAAS therapy helps slow CKD progression and reduce transfusion needs, which is crucial where transplant access is limited. KDIGO’s stepwise approach offers a reproducible framework for outpatient programs in tiered healthcare systems.

Conclusion and next steps with Dr. Vishal Golay (Siliguri)

Anemia in CKD is common, multifactorial, and treatable: optimizing iron and EPO pathways can restore hemoglobin, improve energy, and reduce cardiovascular risk when guided by evidence-based protocols. Early testing for hemoglobin, ferritin, and TSAT, followed by stepwise therapy per KDIGO, is the safest, most effective strategy.

For tailored care in Siliguri, Dr. Vishal Golay’s nephrology service offers:

• Comprehensive anemia workup in CKD, including staging, iron profiling, inflammation assessment, and dialysis-related factors where relevant.
• Individualized treatment plans with IV iron, ESA initiation and monitoring, and consideration of HIF-PHIs where suitable, aligned with the latest KDIGO guidance.
• Integrated CKD management to slow progression, coordinate cardiovascular care, and reduce transfusion dependence through proactive anemia control.